Whanganui Chronicle
  • Whanganui Chronicle home
  • Latest news
  • Sport
  • Business
  • Opinion
  • Lifestyle
  • Property
  • Death notices
  • Classifieds

Subscriptions

  • Herald Premium
  • Viva Premium
  • The Listener
  • BusinessDesk

Sections

  • Latest news
  • On The Up
  • Sport
  • Business
  • Opinion
  • Lifestyle
  • Property
    • All Property
    • Residential property listings
  • Rural
    • All Rural
    • Dairy farming
    • Sheep & beef farming
    • Horticulture
    • Animal health
    • Rural business
    • Rural life
    • Rural technology

Locations

  • Taranaki
  • National Park
  • Whakapapa
  • Ohakune
  • Raetihi
  • Taihape
  • Marton
  • Feilding
  • Palmerston North

Media

  • Video
  • Photo galleries
  • Today's Paper - E-Editions
  • Photo sales
  • Classifieds

Weather

  • New Plymouth
  • Whanganui
  • Palmertson North
  • Levin

NZME Network

  • Advertise with NZME
  • OneRoof
  • Driven Car Guide
  • BusinessDesk
  • Newstalk ZB
  • Sunlive
  • ZM
  • The Hits
  • Coast
  • Radio Hauraki
  • The Alternative Commentary Collective
  • Gold
  • Flava
  • iHeart Radio
  • Hokonui
  • Radio Wanaka
  • iHeartCountry New Zealand
  • Restaurant Hub
  • NZME Events

SubscribeSign In

Advertisement
Advertise with NZME.
Home / Whanganui Chronicle

Ministry approves alternatives to problem thyroid drug

By John Maslin
Whanganui Chronicle·
24 Oct, 2008 12:34 PM2 mins to read

Subscribe to listen

Access to Herald Premium articles require a Premium subscription. Subscribe now to listen.
Already a subscriber?  

Listening to articles is free for open-access content—explore other articles or learn more about text-to-speech.
‌
Save
    Share this article


In the wake of a growing number of complaints about side-effects of a thyroid treatment drug, the Ministry of Health has approved two alternatives.
Medsafe, the ministry's unit responsible for regulating drugs, has given provisional approval to two products containing levothyroxine, giving patients in New Zealand access to an approved alternative to Eltroxin.
The products are Synthroid, manufactured by Abbott Laboratories, which is also sold in Canada, and Levothyroxine, manufactured by Goldshield, which is also sold in the United Kingdom.
The provisional consent limits use of the products to initiation of treatment in new patients, and use in patients who are intolerant or unable to take another brand of levothyroxine.
About a year after its introduction, the numbers of people suffering side effects from Eltroxin increased. The levothyroxine drug is is used to treat hypothyroidism, is a disease where the thyroid gland doesn't produce enough thyroxine, a hormone important to controlling the body's metabolism.
In July last year GlaxoSmithKline, the company producing Eltroxin, announced that this government-subsided drug had undergone a formulation change.
Essentially, its shape, size and colour were changing but nothing else.
As with all drugs Eltroxin had its side effects. But soon after the change was announced, reports about side effects started arriving at the Centre for Adverse Reactions Monitoring at the NZ Pharmacovigilance Centre at the University of Otago. What began as a trickle of reports from people about the drug's side effects has turned into a flood.
With the alternative drugs now available, Medsafe said each company will be required to notify prescribers and pharmacists of the increased need to closely monitor patients who switch brands.
Dr Stewart Jessamine, Medsafe group manager said they were satisfied with their evaluations and that both Levothyroxine and Synthroid were safe and effective alternatives to Eltroxin.
But Dr Jessamine said both products would be carefully monitored.
"While changing to a new levothyroxine product will resolve many of the problems reported by patients taking Eltroxin, patients changing to these new brands will still need to have their blood tests monitored and are likely to require the dose of the new brand adjusted to suit their individual metabolism," he said.
The Goldshield brand will be fully funded from November 1, and full funding will remain for the existing Eltroxin. But Pharnmac said full funding for Synthroid would not be available at this time, however funding may be possible in the future.

Advertisement
Advertise with NZME.
Advertisement
Advertise with NZME.
Save
    Share this article

Latest from Whanganui Chronicle

Whanganui Chronicle

Outgoing Horizons chair says councils 'need to push back'

Whanganui Chronicle

'A huge amount of inertia': RMA reform leaves councils guessing

Whanganui Chronicle

Pilot academy's suspension lifted


Sponsored

Solar bat monitors uncover secrets of Auckland’s night sky

Advertisement
Advertise with NZME.

Recommended for you

The Kiwi troops training Ukraine soldiers
World

The Kiwi troops training Ukraine soldiers

'A lot of deception': French bakery owners vanished, leaving debts unpaid
New Zealand

'A lot of deception': French bakery owners vanished, leaving debts unpaid

Three spectators killed in motor rally accident in France
World

Three spectators killed in motor rally accident in France

Exclusive: Inside the Warriors' plan to become the biggest brand in NZ sport
Warriors

Exclusive: Inside the Warriors' plan to become the biggest brand in NZ sport

How a gang funeral ride brought South Auckland traffic to a standstill
Kahu

How a gang funeral ride brought South Auckland traffic to a standstill

Helicopters fight 12 suspicious fires, including 50ha vegetation blaze
New Zealand

Helicopters fight 12 suspicious fires, including 50ha vegetation blaze



Latest from Whanganui Chronicle

Outgoing Horizons chair says councils 'need to push back'
Whanganui Chronicle

Outgoing Horizons chair says councils 'need to push back'

'The functions we carry out are really important.'

25 Jul 06:00 PM
'A huge amount of inertia': RMA reform leaves councils guessing
Whanganui Chronicle

'A huge amount of inertia': RMA reform leaves councils guessing

25 Jul 05:00 PM
Pilot academy's suspension lifted
Whanganui Chronicle

Pilot academy's suspension lifted

25 Jul 05:00 PM


Solar bat monitors uncover secrets of Auckland’s night sky
Sponsored

Solar bat monitors uncover secrets of Auckland’s night sky

06 Jul 09:47 PM

NZ Herald
  • About NZ Herald
  • Meet the journalists
  • Newsletters
  • Classifieds
  • Help & support
  • Contact us
  • House rules
  • Privacy Policy
  • Terms of use
  • Competition terms & conditions
  • Our use of AI
Subscriber Services
  • Whanganui Chronicle e-edition
  • Manage your print subscription
  • Manage your digital subscription
  • Subscribe to Herald Premium
  • Subscribe to the Whanganui Chronicle
  • Gift a subscription
  • Subscriber FAQs
  • Subscription terms & conditions
  • Promotions and subscriber benefits
NZME Network
  • Whanganui Chronicle
  • The New Zealand Herald
  • The Northland Age
  • The Northern Advocate
  • Waikato Herald
  • Bay of Plenty Times
  • Rotorua Daily Post
  • Hawke's Bay Today
  • Viva
  • NZ Listener
  • Newstalk ZB
  • BusinessDesk
  • OneRoof
  • Driven Car Guide
  • iHeart Radio
  • Restaurant Hub
NZME
  • NZME Events
  • About NZME
  • NZME careers
  • Advertise with NZME
  • Digital self-service advertising
  • Book your classified ad
  • Photo sales
  • © Copyright 2025 NZME Publishing Limited
All Access. All in one subscription. From $2 per week
Subscribe now

All Access Weekly

From $2 per week
Pay just
$15.75
$2
per week ongoing
Subscribe now
BEST VALUE

All Access Annual

Pay just
$449
$49
per year ongoing
Subscribe now
Learn more
30
TOP
search by queryly Advanced Search